Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer.
Fiche publication
Date publication
mai 2013
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MASCAUX Céline
Tous les auteurs :
Zielinski C, Knapp S, Mascaux C, Hirsch F
Lien Pubmed
Résumé
Treatments of non-small-cell lung cancer (NSCLC)-particularly of the squamous subtype-are limited. In this article, we describe the immunomodulatory environment in NSCLC and the potential for therapeutic targeting of the immune system through cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death-1 (PD-1) immune-checkpoint pathway blockade.
Mots clés
Antibodies, Monoclonal, therapeutic use, Antineoplastic Agents, therapeutic use, CTLA-4 Antigen, antagonists & inhibitors, Carcinoma, Non-Small-Cell Lung, drug therapy, Humans, Immunomodulation, Ipilimumab, Lung Neoplasms, drug therapy, Programmed Cell Death 1 Receptor, antagonists & inhibitors
Référence
Ann. Oncol.. 2013 May;24(5):1170-9